Search Result

Results for "

BRCA2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Biochemical Assay Reagents (1) CDK (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (10) Drug Intermediate (1) Endonuclease (2) FLAP (1) NEKs (1) PARP (10) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PROTACs (1) RAD51 (8) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (38) Inflammation/Immunology (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10617A

Rucaparib Maximum Cited Publications 47 Publications Verification AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-10617

Rucaparib phosphate 45+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-177512

MSC778	FLAP	Cancer
MSC778 is an effective and orally active flap endonuclease 1 (FEN1) inhibitor with an IC₅₀ of 3 nM and a K_D of 2.9 nM. MSC778 exhibits 145-fold, 516-fold, and 65-fold selectivity over EXO1, GEN1, and XPG, respectively. MSC778 selectively kills BRCA2-deficient cells and potentiates the activity of Niraparib (HY-10619) to induce tumor stasis in a BRCA2 KO DLD-1 mouse xenograft. MSC778 can be used in the research of colorectal cancer .

HY-124691

D-I03 3 Publications Verification	DNA/RNA Synthesis	Cancer
D-I03 is a selective RAD52 inhibitor with a K_d of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC₅₀s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin ^[2].

HY-122639

ZINC05007751 3 Publications Verification	NEKs	Cancer
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC₅₀ of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .

HY-150147

CAM833 1 Publications Verification	RAD51 Apoptosis	Cancer
CAM833 is a potent orthosteric inhibitor of the interaction between *BRCA2* and RAD51 with a K_d of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .

HY-102003

Rucaparib monocamsylate 35+ Cited Publications AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-151462

RP-6685 3 Publications Verification	DNA/RNA Synthesis	Cancer
RP-6685 is a potent, selective and orally active DNA polymerase theta (Polθ) inhibitor with an IC₅₀ value of 5.8 nM (PicoGreen assay). RP-6685 shows antitumor efficacy in mouse tumor xenograft model . RP-6685 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-148183

Homologous recombination-IN-1	RAD51	Cancer
Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC₅₀=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination .

HY-170844

MU147	Endonuclease	Cancer
MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer activity, which is lethal to Ehrlich ascites tumor cells both in vitro and in vivo. MU147 also eliminates the double-strand break repair mechanism dependent on the MRE11 nuclease activity without impairing the activation of ATM. MU147 also impairs the degradation of nascent strands of stalled replication FOX and selectively affects brca2-deficient cells .

HY-158346

RP-2119	DNA/RNA Synthesis	Cancer
RP-2119 is an orally bioactive Polymerase Theta (Polθ) inhibitor, with an IC₅₀ of 0.7 nM against human Polθ ATPase. RP-2119 reduces Polθ activity and exerts antiproliferative effects in BRCA2-deficient cancer cells. RP-2119 exhibits antitumor activity in BRCA2-deficient cancer cell xenograft mouse models . RP-2119 can be used for the research of cancer and homologous recombination-deficient cancers, including brca1/brca2-mutant cancers and shld2-mutant cancers ^[2].

HY-168993

BRCA2-IN-2	Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
BRCA2-IN-2 (Compound 3i) has a strong binding affinity to the *BRCA2* protein. BRCA2-IN-2 can inhibit the proliferation of breast cancer cells and scavenge DPPH free radicals. BRCA2-IN-2 has anti-tumor and antioxidant activities .

HY-170845

MU1409	Endonuclease	Cancer
MU1409 is an inhibitor of MRE11 nuclease with an IC₅₀ of 12.1 μM. Additionally, MU1409 also inhibits FEN1 and EXO1, with IC₅₀ values of 24.2 and 176.4 μM, respectively. MU1409 affects DNA repair in cells, preventing the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for research on BRCA2 mutation-induced cancers .

HY-161431

RTx-152	DNA/RNA Synthesis	Cancer
RTx-152 traps Polθ on DNA and is an allosteric Polθ-pol inhibitor (IC₅₀: 6.2 nM). RTx-152 selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor resistance in multiple genetic backgrounds, including homologous recombination (HR)-proficient cells. RTx-152 selectively kills BRCA2-null cells .

HY-40041

(R)-1-Boc-3-methyl-piperazine	Biochemical Assay Reagents Drug Intermediate	Cancer
(R)-1-Boc-3-methyl-piperazine (Compound I3-1) is a chemical intermediate. (R)-1-Boc-3-methyl-piperazine can be used for the preparation of Compound I3. Compound I3 exhibits anticancer activity against colorectal adenocarcinoma with BRCA2 gene deletion .

HY-115552

Simmiparib	PARP	Cancer
Simmiparib is a highly potent and orally active PARP1 and *PARP2* inhibitor with IC₅₀ values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib (HY-10162). Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis. Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts .

HY-135782

iso-ADP ribose	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
iso-ADP ribose is the small-molecule ligand for protein nucleic acid modification, comprising parts of two consecutive ADP-ribosyl units within the PAR chain. iso-ADP ribose specifically binds WWE, FHA and OB-fold domains, enabling PAR-dependent functional responses like ubiquitylation and supporting DNA damage signaling and repair. iso-ADP ribose can be used for cancer research .

HY-RS01594

BRCA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRCA2 Human Pre-designed siRNA Set A contains three designed siRNAs for BRCA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRCA2 Human Pre-designed siRNA Set A BRCA2 Human Pre-designed siRNA Set A

HY-RS23267

Brca2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Brca2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Brca2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Brca2 Rat Pre-designed siRNA Set A Brca2 Rat Pre-designed siRNA Set A

HY-162104

BRCA2-RAD51-IN-1	RAD51	Cancer
BRCA2-RAD51-IN-1 (Compound 46) is a *BRCA2-RAD51* inhibitor with an EC₅₀ value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .

HY-153338

C791-0064	DNA/RNA Synthesis Apoptosis	Cancer
C791-0064 is a RAD52 inhibitor. C791-0064 specifically binds to RAD52 and disrupts its single-strand annealing activity. C791-0064 specifically inhibits the proliferation of cancer cells with BRCA2 deficiency, inducing DNA damage and apoptosis (apoptosis). C791-0064 can be used for the study of BRCA mutation-related cancers (such as breast cancer and ovarian cancer) .

HY-173345

BRCA2-RAD51-IN-2	RAD51	Cancer
BRCA2-RAD51-IN-2 (compound S-35d) is a *BRCA2-RAD51* inhibitor and inhibits homologous recombination repair in combination with 10 µM olaparib (HY-10162) .

HY-179219S

RTx-303	DNA/RNA Synthesis	Cancer
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC₅₀ = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer .

HY-122583

D-G23	RAD51	Cancer
D-G23 is a selective RAD52 inhibitor. D-G23 disrupts RAD52-mediated DNA repair pathways and suppresses the growth of BRCA1- and BRCA2-deficient cancer cells. D-G23 is promising for research of homologous recombination-related cancers, such as hereditary breast cancer and ovarian cancer caused by BRCA1/2 mutations .

HY-150958

RAD51-IN-8	RAD51	Cancer
RAD51-IN-8, a new RAD51 binder, is a *RAD51-BRCA2* inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC₅₀ value of 19 μM .

HY-RS16825

Brca2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Brca2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Brca2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Brca2 Mouse Pre-designed siRNA Set A Brca2 Mouse Pre-designed siRNA Set A

HY-173151

BRCA2-IN-1	Reactive Oxygen Species (ROS)	Cancer
BRCA2-IN-1 (Compound 3j) is a potential *BRCA2* inhibitor that exhibits antiproliferative activity against the breast cancer MCF-7 cell lines. BRCA2-IN-1 also demonstrates DPPH radical scavenging ability, with an IC₅₀ of 12.36 µM .

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-135782A

iso-ADP ribose TEA	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
iso-ADP ribose TEA is the small-molecule ligand for protein nucleic acid modification, comprising parts of two consecutive ADP-ribosyl units within the PAR chain. iso-ADP ribose TEA specifically binds WWE, FHA and OB-fold domains, enabling PAR-dependent functional responses like ubiquitylation and supporting DNA damage signaling and repair. iso-ADP ribose TEA can be used for cancer research .

HY-181561

BRCA2-RAD51-IN-3	RAD51	Cancer
BRCA2-RAD51-IN-3 is a *RAD51-BRCA2* protein-protein interaction inhibitor with an EC₅₀ of 29.35 μM and a K_d of 75.14 μM. BRCA2-RAD51-IN-3 blocks RAD51-BRCA2 binding, impairs homologous recombination in cancer cells, and induces synthetic lethality. BRCA2-RAD51-IN-3 acts in human pancreatic cancer cells and shows no activity in normal pancreatic cells. BRCA2-RAD51-IN-3 can be used for the research of pancreatic cancer .

HY-168094

PARP1-IN-30	PARP	Cancer
PARP1-IN-30 (Compound 3) is a specific and potent PARP1 inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of PARP1 in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers .

HY-155766

PARP1-IN-14	PARP Apoptosis	Cancer
PARP1-IN-14 (compound 19k) is a potent PARP1 inhibitor, with an IC₅₀ of 0.6 ± 0.1 nM. PARP1-IN-14 exhibits antiproliferative effect against both MDA-MB-436 (BRCA1 ^−/−) and Capan-1 (BRCA2 ^−/−) cells with IC₅₀ values below 0.3 nM .

HY-10617AR

Rucaparib (Standard) AG014699 (Standard); PF-01367338 (Standard)	Reference Standards PARP	Cancer
Rucaparib (Standard) is the analytical standard of Rucaparib. This product is intended for research and analytical applications. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-163816

Antiproliferative agent-53-d3	Cytochrome P450	Cancer
Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for *CYP2C19* and *CYP2C9* with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-10617R

Rucaparib phosphate (Standard) AG-014699 phosphate (Standard); PF-01367338 phosphate (Standard)	Reference Standards PARP	Cancer
Rucaparib (phosphate) (Standard) is the analytical standard of Rucaparib (phosphate). This product is intended for research and analytical applications. Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-181557

SY-589	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis	Cancer
SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC₅₀=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC₅₀=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing *γ-H2AX* levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors .

HY-179413

Polθ-IN-9	DNA/RNA Synthesis	Cancer
Polθ-IN-9 is an orally active Polθ polymerase inhibitor (IC₅₀ = 9.6 nM, K_d = 47.5 nM). Polθ-IN-9 shows remarkable selectivity with no inhibitory activity against other human DNA polymerases, including Pol α, Pol ε, Pol γ, Pol λ, and Pol μ. Polθ-IN-9 exhibits strong antiproliferative activity in DLD1 BRCA2 KO cells (IC₅₀ = 2.9 μM), and high sensitivity to MDA-MB-436 cells (IC₅₀ = 4.9 μM). Polθ-IN-9 increases DNA damage accumulation, induces γH2AX levels, and inhibits tumor growth in combination with Olaparib (HY-10162), in the MDA-MB-436 xenograft model. Polθ-IN-9 can be used for the research of homologous recombination (HR)-deficient cancers such as breast cancer .

HY-102003R

Rucaparib monocamsylate (Standard) AG014699 monocamsylate (Standard); PF-01367338 monocamsylate (Standard)	Reference Standards PARP	Cancer
Rucaparib monocamsylate (Standard) is the analytical standard of Rucaparib monocamsylate (HY-102003). This product is intended for research and analytical applications. Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-182322

POLQ-IN-1	DNA/RNA Synthesis	Cancer
POLQ-IN-1 is a DNA polymerase θ (POLQ) inhibitor with a pIC₅₀ of 8.2. POLQ-IN-1 inhibits the proliferation of homologous recombination-deficient cells. POLQ-IN-1 is used for the research of homologous recombination-deficient tumors .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	4,096 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

4,096 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

(R)-1-Boc-3-methyl-piperazine	Biochemical Assay Reagents
(R)-1-Boc-3-methyl-piperazine (Compound I3-1) is a chemical intermediate. (R)-1-Boc-3-methyl-piperazine can be used for the preparation of Compound I3. Compound I3 exhibits anticancer activity against colorectal adenocarcinoma with BRCA2 gene deletion .

Cat. No.	Product Name	Target	Research Area

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

Species:	Human (4)
Tag:	SUMO (1) His (3) Tag Free (1) Strep (1) GST (1) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703092

	BRCA2 Protein, Human (HEK293, His, Strep, Flag) FACD; FANCD1	Human	HEK293
	BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.

HY-P76746

	BCCIP Protein, Human (sf9) BRCA2 and CDKN1A-interacting protein; P21- and CDK-associated protein 1; TOK1	Human	Sf9 insect cells
	BCCIP proteins contribute to interphase microtubule organization and anchoring as well as spindle pole organization and stability during mitosis. BCCIP protein may induce cell cycle arrest by enhancing CDK2 inhibition and participate in DNA damage repair through homologous recombination with BRCA2. BCCIP Protein, Human (sf9) is the recombinant human-derived BCCIP protein, expressed by Sf9 insect cells, with tag free.

HY-P76747

	BCCIP Protein, Human (sf9, His-GST) BRCA2 and CDKN1A-interacting protein; P21- and CDK-associated protein 1; TOK1	Human	Sf9 insect cells
	BCCIP proteins contribute to interphase microtubule organization and anchoring as well as spindle pole organization and stability during mitosis. BCCIP protein may induce cell cycle arrest by enhancing CDK2 inhibition and participate in DNA damage repair through homologous recombination with BRCA2. BCCIP Protein, Human (sf9, His-GST) is the recombinant human-derived BCCIP protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P72107

	BRCC36 Protein, Human (His-SUMO) BRCA1-A complex subunit BRCC36; BRCA1/BRCA2 containing complex subunit 3; BRCA1/BRCA2 containing complex subunit 36; BRCA1/BRCA2-containing complex subunit 3; BRCA1/BRCA2-containing complex subunit 36; Brcc3; BRCC3_HUMAN; BRCC36; BRISC complex subunit BRCC36; C6.1A ; Chromosome X open reading frame 53; CXorf53; Lys-63-specific deubiquitinase BRCC36; OTTHUMP00000061450	Human	E. coli
	BRCC36 is a metalloprotease that selectively cleaves "Lys-63" linked polyubiquitin chains, especially histones H2A and H2AX in the BRCA1-A complex during the DNA damage response. As the catalytic subunit of the BRISC complex, it also targets “Lys-63”-linked ubiquitin in various substrates, affecting mitotic spindle assembly and interferon signaling. BRCC36 Protein, Human (His-SUMO) is the recombinant human-derived BRCC36 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-179219S

RTx-303
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC₅₀ = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer .

HY-163816

Antiproliferative agent-53-d3

Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (2) Mouse (2) Monkey (1)
Application:	ICC/IF (1) WB (3) FC (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86790

	BRCA2 Antibody (YA6483) BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; BRCA2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; BRCA2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody;	WB, FC	Human
	BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

HY-P86791

	BRCC45/BRE Antibody (YA6484) 6030405P19Rik antibody; AI429776 antibody; B830038C02Rik antibody; Brain and reproductive organ expressed (TNFRSF1A modulator) antibody; brain and reproductive organ expressed protein antibody; Brain and reproductive organ-expressed protein antibody; BRCA1 A complex subunit BRE antibody; BRCA1-A complex subunit BRE antibody; BRCA1/BRCA2 containing complex subunit 4 antibody; BRCA1/BRCA2 containing complex subunit 45 antibody; 6030405P19Rik antibody; AI429776 antibody; B830038C02Rik antibody; Brain and reproductive organ expressed (TNFRSF1A modulator) antibody; brain and reproductive organ expressed protein antibody; Brain and reproductive organ-expressed protein antibody; BRCA1 A complex subunit BRE antibody; BRCA1-A complex subunit BRE antibody; BRCA1/BRCA2 containing complex subunit 4 antibody; BRCA1/BRCA2 containing complex subunit 45 antibody; BRCA1/BRCA2-containing complex subunit 45 antibody; BRCC4 antibody; BRCC45 antibody; bre antibody; BRE_HUMAN antibody;	WB, ICC/IF, FC	Human, Mouse, Rat
	BRCC45/BRE Antibody (YA6484) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCC45/BRE.

HY-P85527

	Rad51 Antibody (YA5219) BRCA1/BRCA2 containing complex, subunit 5; BRCC 5; BRCC5; DNA repair protein RAD51 homolog 1; DNA repair protein rhp51; HRAD51; HsRad51; HsT16930; MRMV2; Rad 51; RAD51; RAD51 homolog; RecA homolog, E. coli; S. cerevisiae; RAD51 homolog A; RAD51 homolog; RAD51 recombinase; RAD51, S. cerevisiae, homolog of; RAD51_HUMAN; RAD51A; RECA; RecA like protein; RecA, E. coli, homolog of; Recombination protein A.	WB	Human, Mouse, Rat, Monkey
	Rad51 Antibody (YA5219) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Rad51.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: